Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 154
2019 204
2020 177
2021 187
2022 137
2023 214
2024 315
2025 305
2026 141
2027 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,262 results

Results by year

Filters applied: . Clear all
Page 1
Niraparib and Abiraterone Acetate plus Prednisone in Metastatic Castration-resistant Prostate Cancer: Final Overall Survival Analysis for the Phase 3 MAGNITUDE Trial.
Chi KN, Castro E, Attard G, Smith MR, Sandhu S, Efstathiou E, Roubaud G, Small EJ, de Santana Gomes AP, Rathkopf DE, Saad M, Gurney H, Jung W, Kim W, Dibaj S, Wu D, Zhang J, Lopez-Gitlitz A, Francis P, Olmos D. Chi KN, et al. Eur Urol Oncol. 2025 Aug;8(4):986-998. doi: 10.1016/j.euo.2025.04.012. Epub 2025 May 5. Eur Urol Oncol. 2025. PMID: 40328571 Free article. Clinical Trial.
Transperineal Versus Transrectal Magnetic Resonance Imaging-targeted Prostate Biopsy: A Systematic Review and Meta-analysis of Prospective Studies.
Zattoni F, Rajwa P, Miszczyk M, Fazekas T, Carletti F, Carrozza S, Sattin F, Reitano G, Botti S, Matsukawa A, Dal Moro F, Jeffrey Karnes R, Briganti A, Novara G, Shariat SF, Ploussard G, Gandaglia G. Zattoni F, et al. Eur Urol Oncol. 2024 Dec;7(6):1303-1312. doi: 10.1016/j.euo.2024.07.009. Epub 2024 Aug 1. Eur Urol Oncol. 2024. PMID: 39095298 Free article.
Radiotherapy- Versus Surgery-based Treatment Strategy in High-risk Prostate Cancer.
Roy S, Sun Y, Eastham JA, Gleave M, Wallis CJD, Beltran HA, Kishan AU, Jia AY, Zaorsky NG, Nagar H, Garcia JA, Small EJ, Nguyen P, Attard G, McKay RR, Sartor O, Berlin A, Rosenthal SA, Halabi S, Vince R Jr, Ponsky L, Morgan SC, Hannan R, Raben A, Roach M 3rd, Michalski JM, Morris MJ, Sandler HM, Spratt DE. Roy S, et al. Eur Urol Oncol. 2026 Apr;9(2):294-304. doi: 10.1016/j.euo.2025.06.009. Epub 2025 Jul 19. Eur Urol Oncol. 2026. PMID: 40683825 Clinical Trial.
Comparing the Performance of Digital Rectal Examination and Prostate-specific Antigen as a Screening Test for Prostate Cancer: A Systematic Review and Meta-analysis.
Matsukawa A, Yanagisawa T, Bekku K, Kardoust Parizi M, Laukhtina E, Klemm J, Chiujdea S, Mori K, Kimura S, Fazekas T, Miszczyk M, Miki J, Kimura T, Karakiewicz PI, Rajwa P, Shariat SF. Matsukawa A, et al. Eur Urol Oncol. 2024 Aug;7(4):697-704. doi: 10.1016/j.euo.2023.12.005. Epub 2024 Jan 4. Eur Urol Oncol. 2024. PMID: 38182488 Free article.
Clinical Outcomes of Patients with High-risk Metastatic Hormone-naïve Prostate Cancer: A 3-year Interim Analysis of the Observational J-ROCK Study.
Miyake H, Matsumoto R, Fujimoto K, Mizokami A, Uemura H, Kamoto T, Kawakami S, Nakamura K, Maekawa S, Shibayama K, Watanabe A, Ito M, Tajima Y, Matsuyama H, Uemura H. Miyake H, et al. Eur Urol Oncol. 2024 Jun;7(3):625-632. doi: 10.1016/j.euo.2023.12.013. Epub 2024 Jan 30. Eur Urol Oncol. 2024. PMID: 38296736 Free article.
Apalutamide in Metastatic Castration-sensitive Prostate Cancer: Results from the Multicenter Real-world ARON-3 Study.
Santoni M, Büttner T, Rescigno P, Fiala O, Cavasin N, Basso U, Taha T, Massari F, Myint ZW, Formisano L, Galli L, Scagliarini S, Matrana MR, Facchini G, Bamias A, Messina C, Zacchi F, Manneh RK, Roviello G, Santini D, Poprach A, Navratil J, Uher M, Calabrò F, Pierce E, Berardi R, Aurilio G, Zakopoulou R, Rizzo A, Ansari J, Rizzo M, Bisonni R, Mollica V, Incorvaia L, Spinelli G, Jiang XY, Chandler RA, Grillone F, Morelli F, Buti S, Maluf FC, Marques Monteiro FS, Battelli N, Porta C, Caffo O, Soares A. Santoni M, et al. Eur Urol Oncol. 2025 Apr;8(2):444-451. doi: 10.1016/j.euo.2024.11.005. Epub 2024 Nov 29. Eur Urol Oncol. 2025. PMID: 39613567 Free article.
A Deep Prostate-specific Antigen Response to Darolutamide plus Androgen Deprivation Therapy Is Associated with Better Clinical Outcomes in the Phase 3 ARANOTE Trial in Patients with Metastatic Hormone-sensitive Prostate Cancer.
Saad F, Briganti A, Haresh KP, Vjaters E, Olmos D, Littleton N, Testa I, Srinivasan S, Verholen F, Shore N. Saad F, et al. Eur Urol Oncol. 2025 Oct;8(5):1321-1332. doi: 10.1016/j.euo.2025.06.010. Epub 2025 Aug 22. Eur Urol Oncol. 2025. PMID: 40846621 Free article. Clinical Trial.
Real-world Study of Avelumab First-line Maintenance Treatment in Patients with Advanced Urothelial Carcinoma in France: Overall Results from the Noninterventional AVENANCE Study and Analysis of Outcomes by Second-line Treatment.
Barthélémy P, Thibault C, Fléchon A, Gross-Goupil M, Voog E, Eymard JC, Abraham C, Chasseray M, Lorgis V, Hilgers W, Gobert A, Le Moulec S, Simon C, Nicolas E, Escande A, Pouessel D, Mouillet G, Josse C, Solbes MN, Lambert P, Loriot Y. Barthélémy P, et al. Eur Urol Oncol. 2025 Apr;8(2):407-416. doi: 10.1016/j.euo.2024.09.014. Epub 2024 Oct 24. Eur Urol Oncol. 2025. PMID: 39448350 Free article.
1,262 results